Armistice Capital, LLC Bio N Tech Se Transaction History

Armistice Capital, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$122.57 - $153.67 $490,280 - $614,680	-4,000 Reduced 10.0%	36,000 $4.48 Million
Q4 2022 Feb 14, 2023	SELL	$118.43 - $186.05 $13.7 Million - $21.6 Million	-116,000 Reduced 74.36%	40,000 $6.01 Million
Q3 2022 Nov 14, 2022	BUY	$127.65 - $183.11 $7.15 Million - $10.3 Million	56,000 Added 56.0%	156,000 $21 Million
Q2 2022 Aug 15, 2022	BUY	$123.25 - $186.24 $3.08 Million - $4.66 Million	25,000 Added 33.33%	100,000 $14.9 Million
Q1 2022 May 16, 2022	BUY	$126.25 - $231.85 $883,750 - $1.62 Million	7,000 Added 10.29%	75,000 $12.8 Million
Q4 2021 Feb 14, 2022	BUY	$216.64 - $362.52 $3.47 Million - $5.8 Million	16,000 Added 30.77%	68,000 $17.5 Million
Q3 2021 Nov 15, 2021	SELL	$205.93 - $447.23 $2.47 Million - $5.37 Million	-12,000 Reduced 18.75%	52,000 $14.2 Million
Q2 2021 Aug 16, 2021	SELL	$113.32 - $241.49 $24 Million - $51.2 Million	-212,000 Reduced 76.81%	64,000 $14.3 Million
Q1 2021 May 17, 2021	BUY	$85.73 - $119.5 $3.43 Million - $4.78 Million	40,000 Added 16.95%	276,000 $30.1 Million
Q4 2020 Feb 16, 2021	SELL	$72.71 - $129.54 $7.27 Million - $13 Million	-100,000 Reduced 29.76%	236,000 $19.2 Million
Q3 2020 Nov 16, 2020	BUY	$57.81 - $104.17 $19.4 Million - $35 Million	336,000 New	336,000 $23.3 Million

357

38.3M

2.45M

2.29M

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $27.4B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

Get notified when there are updates to the investment portfolio of Armistice Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Armistice Capital, LLC with notifications on news.